A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor

Phase 4

Completed

• Conditions: Hereditary Factor VIII Deficiency Disease With Inhibitor
• Interventions: Drug: aPCC, aPCC + TXA; Drug: rFVIIa, rFVIIa + TXA

• Registration Number: NCT01800435
• Lead Sponsor: Oslo University Hospital

Brief Summary

Activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) are the only two drugs that are available to treat bleeds in haemophilia A patients with high titer inhibitors. However, management of bleeds in these patients can be challenging due to variation in response and lack of standardized methods to monitor the effect. We hypothesized that significant increase in whole blood clot stability could be achieved when tranexamic acid was given concomitantly with bypassing-agents while thrombin generation remains unaffected. In this prospective crossover study the effect of aPCC and rFVIIa with and without TXA on clot stability and thrombin generation capacity (ETP) were studied, using thromboelastography (ROTEM) and thrombin generation assay (TGA), respectively. In addition, the risk of thrombosis and disseminated intravascular coagulation (DIC) was assessed.

Detailed Description

Patients receive the first day aPCC (75IU/kg) and aPCC in addition to TXA (20mg/kg orally) the second day. After a 14 days washout period they crosse over using rFVIIa (90 µg/kg) otherwise the same experimental setup. Blood sampling is performed at baseline, 15, 30, 60, 120, 180 and 240 minutes post-treatment.

Study Timeline

• Study Start: 2011-10
• Primary Completion: 2012-10
• Study Completion: 2012-10
• Status Verified: 2013-02
• Study First Submitted: 2013-02-15
• Study First Submitted QC: 2013-02-25
• Study First Posted: 2013-02-27
• Last Update Submitted: 2013-02-28
• Last Update Posted: 2013-03-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

• Haemophilia patients with high titer inhibitors or high-responding inhibitors, aged between 18-65 and no history of aspirin or NSAID use within the last 14 days were eligible for the study.

Exclusion Criteria

• Patients with renal failure, liver disease, infected with immune deficiency virus (HIV), platelet count <150x109/L, acquired haemophilia, ongoing bleeding, hypersensitivity to TXA or a history of arterial or venous thrombosis were excluded from the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
aPCC, aPCC + TXA	aPCC, aPCC + TXA	aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
aPCC, aPCC + TXA	rFVIIa, rFVIIa + TXA	aPCC 75IU/kg i.v aPCC 75IU/kg i.v +TXA 20mg/kg
rFVIIa, rFVIIa + TXA	aPCC, aPCC + TXA	rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg
rFVIIa, rFVIIa + TXA	rFVIIa, rFVIIa + TXA	rFVIIa 90 µg/kg i.v rFVIIa 90 µg/kg i.v + TXA 20 mg/kg

Primary Outcome Measures

Name	Time	Method
Clot stability and thrombin generation capacity following treatment with bypassing agents with and without tranexamic acid.	2 years	MCF (maximum clot formation/mm x 100-1), AUC (area under the elasticity curve AUC, mm• 100 s-1) were used as the primary outcome measures for evaluating clot stability and (ETP) the coagulable state.

Secondary Outcome Measures

Name	Time	Method
DIC or thrombosis events associated with different treatment regimens.	2 years	DIC parameters such as aPTT, PT/INR, platelet count, fibrinogen and D-dimer with the scoring system proposed by the International Society of Thrombosis and Haemostasis were used to monitor DIC in addition to common clinical signs associated with DIC were records. Symptoms or clinical signs of thrombosis such as dyspnea, chest pain, legg swelling or discomfort/pain were recorded.

Trial Locations

Locations (1)

Oslo University Hospital; 🇳🇴 Oslo, Norway